1625-11-2

Usage

Uses

Used in Pharmaceutical Industry:
6α-Methyl Hydrocortisone 21-Acetate is used as an active pharmaceutical ingredient (API) for the development of medications targeting inflammation and immune system disorders. Its potent anti-inflammatory and immunosuppressive properties make it effective in treating conditions such as rheumatoid arthritis, lupus, asthma, and various skin diseases.
Used in Steroid Hormone Replacement Therapy:
In the field of endocrinology, 6α-Methyl Hydrocortisone 21-Acetate is used as a steroid hormone replacement therapy for patients with adrenal insufficiency or other conditions requiring glucocorticoid supplementation. It helps to maintain normal physiological functions and alleviate symptoms associated with hormone deficiency.
Used in Veterinary Medicine:
6α-Methyl Hydrocortisone 21-Acetate is also utilized in veterinary medicine as an anti-inflammatory and immunosuppressive agent for the treatment of various conditions in animals, such as allergies, skin diseases, and inflammatory bowel disease.
Used in Research and Development:
As a USP impurity, 6α-Methyl Hydrocortisone 21-Acetate is employed in the research and development of new drugs and therapies. It serves as a reference compound for quality control, stability testing, and method development in the pharmaceutical industry, ensuring the safety and efficacy of medications containing glucocorticoids.

InChI:InChI=1/C24H34O6/c1-13-9-16-17-6-8-24(29,20(28)12-30-14(2)25)23(17,4)11-19(27)21(16)22(3)7-5-15(26)10-18(13)22/h10,13,16-17,19,21,27,29H,5-9,11-12H2,1-4H3/t13-,16-,17-,19-,21+,22-,23-,24-/m0/s1

Upstream product

• 3386-05-8 21-acetoxy-11β-hydroxy-6α-methyl-pregna-4,17(20)c-dien-3-one 
• 123292-91-1 (20Ξ)-11β-hydroxy-6α-methyl-17,20;20,21-bis-methylenedioxy-pregn-4-en-3-one 
• 53-06-5 17,21-dihydroxy-pregn-4-ene-3,11,20-trione 
• 3607-68-9 17α,20;20,21-bismethylenedioxypregn-4-ene-3,11-dione 
• 123885-50-7 (20Ξ)-3,3-ethanediyldioxy-6β-hydroxy-6α-methyl-17,20;20,21-bis-methylenedioxy-5α-pregnan-11-one 
• 107157-45-9 (20Ξ)-3,3-ethanediyldioxy-17,20;20,21-bis-methylenedioxy-5α-pregnane-6,11-dione 
• 1625-39-4 11β,17α,21-trihydroxy-6α-methylpregna-4-ene-3,20-dione 
• 108-24-7 acetic anhydride 
• 52248-40-5 (8′S,9′S,10′R,13′S,14′S,17′R)-10′,13′-dimethyl-1′,2′,4′,7′,8′,9′,10′,12′,13′,14′,15′,16′-dodecahydro-11′H-trispiro[[1,3]dioxolane-2,3′-cyclopenta[a]phenanthrene-17′,4''-[1,3]dioxolane-5'',4'''-[1,3]dioxolan]-11′-one 
• 55701-21-8 (20Ξ)-17,20;20,21-bis-methylenedioxy-5α-pregnane-3,6,11-trione 
• 113251-88-0 5,11β,17-trihydroxy-6β-methyl-5α-pregnane-3,20-dione 
• 7055-53-0 11β,17-dihydroxy-6α-methyl-pregn-4-ene-3,20-dione 

Downstream Products

• 1625-39-4 11β,17α,21-trihydroxy-6α-methylpregna-4-ene-3,20-dione 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

9α-dehalogenation process

The present invention involves improved processes for the dehalogenation of 9α-halosteroids (I) STR1 to produce the corresponding 11β-hydroxy steroids (II) STR2 which are known to be useful as pharmaceutical, where the improvements comprise (1) adding the 9α-halo steroid (I) to the chromium and (2) using catalytic amounts of chromium in the presence of a means of converting chromium (II) to chromium (III).

Process and intermediates for the preparation of 17 alphahydroxyprogesterones and corticoids from an enol steroid

This invention discloses an improved process for the production of corticoids from 17α-hydroxy steroids utilizing peroxymonosulfate.